Trial Profile

A placebo-controlled clinical trial of obeticholic acid (OCA) in subjects with fibrotic stages of Non-Alcoholic SteatoHepatitis (NASH)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obeticholic acid (Primary)
Indications Non-alcoholic steatohepatitis
Focus Therapeutic Use
Acronyms INTERCEPT 747-117

Most Recent Events

11 Apr 2019 New trial record
04 Apr 2019 According to a HepQuant media release, results from this trial will be presented as a Late Breaker poster (LBP-18) at International Liver Congress 2019, the 54th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria April 10-14, 2019.
04 Apr 2019 Disease Severity Index (DSI) results presented in the HepQuant media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com